Abstract: The various aspects presented herein relate to flavoring compositions with smoky-like aroma profile for use in flavored consumer products, and methods for the preparation of such flavoring compositions.

Abstract: The present disclosure generally provides uses of certain mixed hydroxy- and methoxy-substituted flavones (HMFs) to reduce bitterness, astringency, or sourness, or to enhance sweetness of a ingestible composition, such as a flavored food or beverage product. In some embodiments, the disclosure provides uses of the HMFs disclosed herein to reduce the unpleasant taste of limonin, nomelin, or naringin, which can be present at elevated levels in certain citrus products.

Abstract: The present disclosure generally provides uses of certain mixed hydroxy- and methoxy-substituted flavanones (HMFs) to reduce bitterness, astringency, or sourness, or to enhance sweetness of a ingestible composition, such as a flavored food or beverage product. In some embodiments, the disclosure provides uses of the HMFs disclosed herein to reduce the unpleasant taste of limonin, nomelin, or naringin, which can be present at elevated levels in certain citrus products.

Abstract: Some embodiments of the disclosure provide a method for measuring lesion features of hypertensive retinopathy. In some examples, the method includes: acquiring a fundus image (s110); identifying an optic disc region of the fundus image and dividing the fundus image into at least three regions including a first region (c1), a second region (c2), and a third region (c3) on the basis of the optic disc region (b) (s120); performing artery and vein segmentation on the fundus image by a deep learning-based arteriovenous segmentation model to obtain the arteriovenous segmentation result (s130), the arteriovenous vessel annotation results including an artery annotation result (e1), a vein annotation result (e2), and a small vessel annotation result (e3); and measuring lesion features in the fundus image on the basis of the three regions (c1, c2, c3) and the arteriovenous segmentation result (s140).

Abstract: Provided herein is a method of improving the taste profile of a glucosylated terpene glycoside (GTG).

Abstract: The present disclosure generally provides conjugates diynes, particularly 6,8-diyne amides, and the use of such compounds and related compounds as flavor modifiers. In some aspects, the disclosure provides compositions that include such conjugated diynes, such as compositions that include such conjugated diynes and one or more additional compounds, such as a sweetener, salt, a glutamate, an arginate, and the like. In some other aspects, the disclosure provides methods of reducing or eliminating the amount of sweetener, salt, glutamate, or arginate in a food or beverage product.

Abstract: The present disclosure relates generally to malonyl steviol glycosides and the use of such compounds for various comestible uses, such as sweetening a flavored product or enhancing the sweetness of another sweetener. In some aspects, the disclosure provides certain compositions that include such malonyl steviol glycosides, such as compositions that include such malonyl steviol glycosides and one or more other sweeteners. In some other aspects, the disclosure provides methods of reducing the caloric content of a flavored article, such as a flavored food or beverage product, or an oral care product.

Abstract: The present disclosure provides compositions containing: 2-(3,4-dimethoxyphenyl)-5,6,7-trimethoxychromen-4-one (“sinensetin”); 3,5,6,7,8,3?,4?-heptamethoxyflavone (“heptamethoxyflavone” or “HMF”); 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one (“nobiletin”); 5,6,7,4?-tetramethoxyflavone (“tetra-O-methylscutellarein” or “TMS”); 3,5,6,7,3?,4?-hexamethoxyflavone (“hexamethoxyquercetogetin” or “HMQ”); 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one (“tangeretin”); or any combinations thereof. The disclosure also provides uses of such compositions as mouthfeel enhancers or bitterness maskers of flavored articles, such as beverages.

Abstract: Provided herein is a method of improving the taste profile of a glucosylated terpene glycoside (GTG).

Abstract: Provided herein is a method of improving the taste profile of a glucosylated terpene glycoside (GTG) comprising: a) mixing a malted cereal with a glucosylated terpene glycosides in water to form a GTG cereal mixture wherein the cereal comprises an amylase; b) adjusting the temperature of the mixture to a temperature sufficient to activate the amylase and for a time sufficient to form a mixture comprising glycosylated steviol glycosides wherein the average number of glucose units of the GTG in the GTG cereal mixture is reduced.

Abstract: The present disclosure provides compositions that include tetra-O-methylscutellarein, hexamethoxyquercetagetin, or mixtures or combinations thereof, as well as their use as sweeteners or sweetness enhancers.

Abstract: Provided herein is a method of improving the taste profile of a glucosylated terpene glycoside (GTG) comprising: a) mixing a malted cereal with a glucosylated terpene glycosides in water to form a GTG cereal mixture wherein the cereal comprises an amylase; b) adjusting the temperature of the mixture to a temperature sufficient to activate the amylase and for a time sufficient to form a mixture comprising glycosylated steviol glycosides wherein the average number of glucose units of the GTG in the GTG cereal mixture is reduced.

Abstract: A new use of a compound as indicated in structural formula I in preparing medications for preventing and/or treating pulmonary fibrosis includes the compound having the structure as indicated in structural formula 1 that substantially reduces the inflammation of diseased lung tissue, lowers the concentration of fibrosis factors TGF-?I in diseased lung tissue, decreases the excessive deposition of collagen in diseased lung tissue, and has substantial prevention and treatment effectiveness against fibrosis.

Abstract: A new use of a compound as indicated in structural formula I in preparing medications for preventing and/or treating pulmonary fibrosis includes the compound having the structure as indicated in structural formula 1 that substantially reduces the inflammation of diseased lung tissue, lowers the concentration of fibrosis factors TGF-?I in diseased lung tissue, decreases the excessive deposition of collagen in diseased lung tissue, and has substantial prevention and treatment effectiveness against fibrosis.

Abstract: The present invention provides a receiver for receiving digital signals including frames with a binary modulated cyclic preamble, comprising: means for correlating at least part of a first cyclic preamble in a first frame and at least part of a second cyclic preamble in a second frame, and for determining a carrier frequency offset based on said correlation.

Abstract: A method for determining location information used in an electronic device of a communication system including a plurality of electronic devices, comprising: transmitting a position request signal via a plurality of communication networks of the communication system; receiving a position response signal with respective location information from at least one electronic devices of the plurality of electronic devices; and determining position information of the electronic device by the received position response signal; wherein the position request signal is transmitted successively to the plurality of networks in a specific order among said networks until the location information of the electronic device is determined based on the location response signal.

Abstract: The present invention provides a receiver for receiving digital signals including frames with a binary modulated cyclic preamble, comprising: means for correlating at least part of a first cyclic preamble in a first frame and at least part of a second cyclic preamble in a second frame, and for determining a carrier frequency offset based on said correlation.